1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial

The Lancet 2026

View at publisher
Authors: Yohei Sotomi, Ken Kozuma, Yoshiharu Higuchi, Gaku Nakazawa, Yoshihiro Morino, Kenji Ando, Junya Ako, Kengo Tanabe, Takashi Muramatsu, Ken Kobayashi, Yasuhiro Ichibori, Takayuki Ishihara
+12 more Keiji Hirooka, Satoru Suwa, Takayuki Warisawa, Toru Naganuma, Atsushi Kikuchi, Ryu Shutta, Naotaka Okamoto, Yasuhiro Tanabe, Atsunori Okamura, Kosuke Kashiwabara, Shungo Hikoso, Yasushi Sakata
DOI: 10.1016/s0140-6736(26)00665-3
Cited by: 1
References: 35

Fields of Study & Subjects

Atrial Fibrillation Management and Outcomes Coronary Interventions and Diagnostics Antiplatelet Therapy and Cardiovascular Diseases

Publication details

Journal / source
The Lancet
Publisher
Elsevier BV
Volume
408
Issue
10553
Pages
440–452
Publication date
16 July 2026
Language
EN